suramin has been researched along with Neoplasms in 43 studies
Suramin: A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties.
suramin : A member of the class of phenylureas that is urea in which each of the amino groups has been substituted by a 3-({2-methyl-5-[(4,6,8-trisulfo-1-naphthyl)carbamoyl]phenyl}carbamoyl)phenyl group. An activator of both the rabbit skeletal muscle RyR1 and sheep cardiac RyR2 isoform ryanodine receptor channels, it has been used for the treatment of human African trypanosomiasis for over 100 years.
Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This experience suggests the avoidance of elective procedures during the first month after suramin therapy and a heightened awareness of the potential for bleeding and wound healing problems in patients receiving suramin who do require an emergent procedure." | 7.69 | Postoperative complications in patients receiving suramin therapy. ( Cole, DJ; Cooper, MR; Danforth, DN; Ettinghausen, SE; Linehan, MW; Myers, CW; Pass, HI; Sindelar, WF, 1994) |
| "Suramin is a polysulfonated compound originally developed nearly 75 years ago for use as a trypanocidal agent." | 3.76 | Suramin: prototype of a new generation of antitumor compounds. ( La Rocca, RV; Myers, CE; Stein, CA, 1990) |
| "This experience suggests the avoidance of elective procedures during the first month after suramin therapy and a heightened awareness of the potential for bleeding and wound healing problems in patients receiving suramin who do require an emergent procedure." | 3.69 | Postoperative complications in patients receiving suramin therapy. ( Cole, DJ; Cooper, MR; Danforth, DN; Ettinghausen, SE; Linehan, MW; Myers, CW; Pass, HI; Sindelar, WF, 1994) |
| " The purpose of this study was to determine the maximum tolerated dose and toxicities of suramin when administered using a fixed dosing scheme on a once- or twice-monthly schedule." | 2.70 | A phase I study of suramin with once- or twice-monthly dosing in patients with advanced cancer. ( Janisch, L; Kobayashi, K; Ratain, MJ; Ryan, CW; Vogelzang, NJ; Vokes, EE, 2002) |
| "Suramin was administered to 49 patients in a Phase I cancer trial with real-time pharmacokinetic monitoring and dose individualization to achieve targeted mean plasma concentrations of 210 and 155 mg/liter during the 7-day period between days 15 and 22." | 2.69 | Renal clearance, tissue distribution, and CA-125 responses in a phase I trial of suramin. ( Alberti, D; Arzoomanian, R; Cheng, AL; Church, D; Hutson, PR; Kehrli, N; Marnocha, R; Pomplun, M; Rago, R; Tutsch, KD; Wilding, G, 1998) |
| "Suramin is a promising agent for the treatment of hormone-refractory metastatic prostate cancer." | 2.68 | Phase I study of suramin given by intermittent infusion without adaptive control in patients with advanced cancer. ( Janish, L; Kobayashi, K; Ratain, MJ; Soliven, B; Vogelzang, NJ; Vokes, EE, 1995) |
| "Suramin is a polysulfonated polyaromatic symmetrical urea." | 2.44 | Suramin: clinical uses and structure-activity relationships. ( Bennett, AJ; Cosgrove, KL; McGeary, RP; Ross, BP; Tran, QB, 2008) |
| "Peripheral neurotoxicity is a crucial side effect of chemotherapeutic agents." | 2.41 | [Peripheral nervous system neurotoxicity secondary to chemotherapy treatment] . ( Iñiguez, C; Larrodé, P; Mauri, JA; Mayordomo, JI; Morales, F; Trés, A, 2000) |
| "General principles for anticancer drug development include traditional drug-screening methods in biological test systems." | 2.39 | Current concepts of treatment in medical oncology: new anticancer drugs. ( Unger, C, 1996) |
| " In all cases, considerable effort has gone into detailed pharmacokinetic studies conducted before and during the clinical phase I studies." | 2.38 | Pharmacokinetics and early clinical studies of selected new drugs. ( Cassidy, J; Graham, MA; Jodrell, D; Kaye, SB; Workman, P, 1993) |
| "In three human cancer cells that depend on telomerase for telomere maintenance (pharynx FaDu, prostate PC3, breast MCF7), suramin inhibited telomerase activity in cell extracts and intact cells at concentrations that exhibited no cytotoxicity (IC50 of telomerase was between 1 and 3 μM vs." | 1.42 | Pharmacodynamics of telomerase inhibition and telomere shortening by noncytotoxic suramin. ( Au, JL; Cottage, CT; Gan, Y; Lu, J; Wientjes, MG; Yeung, BZ, 2015) |
| "Suramin's effects were not caused by accumulation of cells in a specific phase of the cell cycle." | 1.32 | Suramin sensitizing cells to ionizing radiation by inactivating DNA-dependent protein kinase. ( Enomoto, A; Green, J; Hosoi, Y; Matsumoto, Y; Morita, A; Nakagawa, K; Naruse, K; Suzuki, N, 2004) |
| "Suramin is an experimental anti-neoplastic agent which has shown promising activity against prostatic carcinoma and lymphoma in clinical trials." | 1.29 | Suramin sodium: pronounced effects on methotrexate transport and anti-folate activity in cultured tumor cells. ( Bustamante, A; Henderson, GB; Patel, R; Rideout, DC, 1995) |
| "Suramin is an anticancer agent with a narrow therapeutic window and a terminal half-life of 45 to 55 days." | 1.28 | Suramin: rapid loading and weekly maintenance regimens for cancer patients. ( Heimans, JJ; Lopez, R; Meijer, E; Pinedo, HM; van Groeningen, CJ; van Loenen, AC; van Rijswijk, RE; Wagstaff, J, 1992) |
| "Suramin was used to analyze the growth-effects of blockade of iron uptake on two established human cell lines, U-937 (monocytoid) and K-562 (erythroleukemic)." | 1.27 | Role of iron in the proliferation of the established human tumor cell lines U-937 and K-562: effects of suramin and a lipophilic iron chelator (PIH). ( Bjelkenkrantz, K; Forsbeck, K; Nilsson, K, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (4.65) | 18.7374 |
| 1990's | 28 (65.12) | 18.2507 |
| 2000's | 10 (23.26) | 29.6817 |
| 2010's | 2 (4.65) | 24.3611 |
| 2020's | 1 (2.33) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, X | 1 |
| Shi, S | 1 |
| Su, Y | 1 |
| Yang, X | 2 |
| He, S | 1 |
| Wu, J | 1 |
| Zhang, J | 1 |
| Rao, F | 1 |
| Igoli, NP | 1 |
| Obanu, ZA | 1 |
| Gray, AI | 1 |
| Clements, C | 1 |
| Gan, Y | 1 |
| Lu, J | 1 |
| Yeung, BZ | 1 |
| Cottage, CT | 1 |
| Wientjes, MG | 1 |
| Au, JL | 1 |
| McGeary, RP | 1 |
| Bennett, AJ | 1 |
| Tran, QB | 1 |
| Cosgrove, KL | 1 |
| Ross, BP | 1 |
| Ryan, CW | 1 |
| Vokes, EE | 4 |
| Vogelzang, NJ | 4 |
| Janisch, L | 2 |
| Kobayashi, K | 4 |
| Ratain, MJ | 4 |
| KEIL, E | 1 |
| Hosoi, Y | 1 |
| Matsumoto, Y | 1 |
| Enomoto, A | 1 |
| Morita, A | 1 |
| Green, J | 1 |
| Nakagawa, K | 1 |
| Naruse, K | 1 |
| Suzuki, N | 1 |
| Turyna, B | 1 |
| Jurek, A | 1 |
| Gotfryd, K | 1 |
| Siaśkiewicz, A | 1 |
| Kubit, P | 1 |
| Klein, A | 1 |
| Cavaletti, G | 1 |
| Marmiroli, P | 1 |
| Bahramsoltani, M | 1 |
| Plendl, J | 1 |
| Lin, CY | 1 |
| Tseng, IC | 1 |
| Chou, FP | 1 |
| Su, SF | 1 |
| Chen, YW | 1 |
| Johnson, MD | 1 |
| Dickson, RB | 1 |
| Bicknell, R | 1 |
| Firsching, A | 1 |
| Nickel, P | 1 |
| Mora, P | 1 |
| Allolio, B | 1 |
| Janish, L | 1 |
| Soliven, B | 2 |
| Rideout, DC | 1 |
| Bustamante, A | 1 |
| Patel, R | 1 |
| Henderson, GB | 1 |
| Soulie, P | 1 |
| Cvitkovic, E | 2 |
| Armand, JP | 2 |
| Eisenberger, MA | 1 |
| Reyno, LM | 1 |
| Cole, DJ | 1 |
| Ettinghausen, SE | 1 |
| Pass, HI | 1 |
| Danforth, DN | 1 |
| Linehan, MW | 1 |
| Myers, CW | 1 |
| Cooper, MR | 1 |
| Sindelar, WF | 1 |
| Kaye, SB | 1 |
| Workman, P | 1 |
| Graham, MA | 1 |
| Cassidy, J | 2 |
| Jodrell, D | 1 |
| Rebollo, J | 1 |
| Voogd, TE | 1 |
| Vansterkenburg, EL | 1 |
| Wilting, J | 1 |
| Janssen, LH | 1 |
| Unger, C | 1 |
| Estrov, Z | 1 |
| Kurzrock, R | 1 |
| Talpaz, M | 1 |
| Strassmann, G | 1 |
| Kambayashi, T | 1 |
| Hutson, PR | 1 |
| Tutsch, KD | 1 |
| Rago, R | 1 |
| Arzoomanian, R | 1 |
| Alberti, D | 1 |
| Pomplun, M | 1 |
| Church, D | 1 |
| Marnocha, R | 1 |
| Cheng, AL | 1 |
| Kehrli, N | 1 |
| Wilding, G | 1 |
| Iñiguez, C | 1 |
| Larrodé, P | 1 |
| Mayordomo, JI | 1 |
| Mauri, JA | 1 |
| Trés, A | 1 |
| Morales, F | 1 |
| Zhang, W | 1 |
| Chen, S | 1 |
| Zogakis, TG | 1 |
| Libutti, SK | 1 |
| Fleming, TP | 1 |
| Matsui, T | 1 |
| Heidaran, MA | 1 |
| Molloy, CJ | 1 |
| Artrip, J | 1 |
| Aaronson, SA | 1 |
| van Rijswijk, RE | 2 |
| van Loenen, AC | 1 |
| Wagstaff, J | 1 |
| Meijer, E | 1 |
| Lopez, R | 1 |
| van Groeningen, CJ | 1 |
| Heimans, JJ | 1 |
| Pinedo, HM | 2 |
| Bai, L | 1 |
| Naomoto, Y | 1 |
| Miyazaki, M | 1 |
| Orita, K | 1 |
| Namba, M | 1 |
| Horne, MK | 1 |
| Wilson, OJ | 1 |
| Cooper, M | 1 |
| Gralnick, HR | 1 |
| Myers, CE | 3 |
| Klijn, JG | 1 |
| Myers, C | 1 |
| La Rocca, RV | 2 |
| Meer, J | 1 |
| Gilliatt, RW | 1 |
| Stein, CA | 2 |
| Dalakas, MC | 1 |
| Zaniboni, A | 1 |
| Forsbeck, K | 1 |
| Bjelkenkrantz, K | 1 |
| Nilsson, K | 1 |
17 reviews available for suramin and Neoplasms
| Article | Year |
|---|---|
Suramin: clinical uses and structure-activity relationships.
Topics: Animals; Antineoplastic Agents; Humans; Neoplasms; Onchocerciasis; Structure-Activity Relationship; | 2008 |
Chemotherapy-induced peripheral neurotoxicity.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Epothilones; Humans; Neoplasms; Neuroprote | 2004 |
Zymogen activation, inhibition, and ectodomain shedding of matriptase.
Topics: Amino Acid Motifs; Animals; Antibodies, Monoclonal; Cytosol; Gene Expression Regulation, Enzymologic | 2008 |
Vascular targeting and the inhibition of angiogenesis.
Topics: Angiogenesis Inducing Agents; Angiogenesis Inhibitors; Antineoplastic Agents; Cyclohexanes; Endothel | 1994 |
Suramin.
Topics: Drug Administration Schedule; Drug Monitoring; Humans; Male; Neoplasms; Prostatic Neoplasms; Suramin | 1994 |
Pharmacokinetics and early clinical studies of selected new drugs.
Topics: Animals; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Agents; Aziridines; Camptotheci | 1993 |
[Suramin: pharmacology and antitumor effectiveness of an old parasiticide].
Topics: Humans; Neoplasms; Suramin | 1994 |
Recent research on the biological activity of suramin.
Topics: Acquired Immunodeficiency Syndrome; Animals; Filarioidea; Humans; Neoplasms; Onchocerciasis; Recepto | 1993 |
Current concepts of treatment in medical oncology: new anticancer drugs.
Topics: Animals; Antineoplastic Agents; Drug Design; Drug Resistance; Humans; Mice; Neoplasms; Suramin; Topo | 1996 |
Interleukin-1 and its inhibitors: implications for disease biology and therapy.
Topics: Animals; Antineoplastic Agents; Bone Marrow Diseases; Caspase 1; Cysteine Endopeptidases; Gene Expre | 1995 |
Inhibition of experimental cancer cachexia by anti-cytokine and anti-cytokine-receptor therapy.
Topics: Animals; Antibodies; Cachexia; Cytokines; Humans; Interleukin-6; Mice; Mice, Inbred Strains; Neoplas | 1995 |
[Peripheral nervous system neurotoxicity secondary to chemotherapy treatment] .
Topics: Anti-HIV Agents; Antineoplastic Agents; Cyclosporine; Depsipeptides; Docetaxel; Doxorubicin; Humans; | 2000 |
General aspects of anti-angiogenesis and cancer therapy.
Topics: Angiogenesis Inhibitors; Animals; Antibodies; Clinical Trials as Topic; Collagen; Cyclohexanes; Endo | 2001 |
Peptide growth factors: the parallel between fetal development and malignant transformation.
Topics: Antibodies, Monoclonal; Cell Transformation, Neoplastic; Embryonic and Fetal Development; Fibroblast | 1991 |
Suramin: a new therapeutic concept.
Topics: Antineoplastic Agents; Growth Inhibitors; Humans; Neoplasms; Nervous System; Suramin | 1990 |
Suramin: prototype of a new generation of antitumor compounds.
Topics: Clinical Trials as Topic; Humans; Neoplasms; Suramin; Tumor Cells, Cultured | 1990 |
Suramin: the discovery of an old anticancer drug.
Topics: Animals; Antineoplastic Agents; Humans; Neoplasms; Suramin | 1990 |
5 trials available for suramin and Neoplasms
| Article | Year |
|---|---|
A phase I study of suramin with once- or twice-monthly dosing in patients with advanced cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biological Availability; Drug Monitoring; Fem | 2002 |
Phase I study of suramin given by intermittent infusion without adaptive control in patients with advanced cancer.
Topics: Adaptation, Physiological; Adult; Aged; Cohort Studies; Drug Administration Schedule; Drug Monitorin | 1995 |
Interleukin-1 and its inhibitors: implications for disease biology and therapy.
Topics: Animals; Antineoplastic Agents; Bone Marrow Diseases; Caspase 1; Cysteine Endopeptidases; Gene Expre | 1995 |
Renal clearance, tissue distribution, and CA-125 responses in a phase I trial of suramin.
Topics: Adult; Affect; Aged; Antineoplastic Agents; Blood Cell Count; CA-125 Antigen; Female; Hemoglobins; H | 1998 |
Suramin: prototype of a new generation of antitumor compounds.
Topics: Clinical Trials as Topic; Humans; Neoplasms; Suramin; Tumor Cells, Cultured | 1990 |
23 other studies available for suramin and Neoplasms
| Article | Year |
|---|---|
Suramin and NF449 are IP5K inhibitors that disrupt inositol hexakisphosphate-mediated regulation of cullin-RING ligase and sensitize cancer cells to MLN4924/pevonedistat.
Topics: Benzenesulfonates; Cullin Proteins; Cyclopentanes; Enzyme Inhibitors; HCT116 Cells; HEK293 Cells; Hu | 2020 |
Bioactive diterpenes and sesquiterpenes from the rhizomes of wild ginger (Siphonochilus aethiopicus (Schweinf) B.L Burtt).
Topics: Animals; Anti-Bacterial Agents; Antineoplastic Agents, Phytogenic; Cell Line; Diterpenes; Hep G2 Cel | 2012 |
Pharmacodynamics of telomerase inhibition and telomere shortening by noncytotoxic suramin.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Dose-Response Relationship, Drug; Humans; Inhibito | 2015 |
[Inhibition of growth of neoplasms by Bayer 205].
Topics: Humans; Neoplasms; Physiological Phenomena; Suramin | 1952 |
Suramin sensitizing cells to ionizing radiation by inactivating DNA-dependent protein kinase.
Topics: Cell Line; Cell Line, Tumor; Cell Survival; DNA-Activated Protein Kinase; DNA-Binding Proteins; Dose | 2004 |
Peritonitis-induced antitumor activity of peritoneal macrophages from uremic patients.
Topics: Antineoplastic Agents; Apoptosis; Cell Line; Cell Line, Transformed; Cell Line, Tumor; Cell Prolifer | 2004 |
Different ways to antiangiogenesis by angiostatin and suramin, and quantitation of angiostatin-induced antiangiogenesis.
Topics: Angiogenesis Inhibitors; Angiostatins; Animals; Antineoplastic Agents; Endothelium, Vascular; Neopla | 2007 |
Antiproliferative and angiostatic activity of suramin analogues.
Topics: Antineoplastic Agents; Cell Division; Humans; Neoplasms; Neovascularization, Pathologic; Structure-A | 1995 |
Suramin sodium: pronounced effects on methotrexate transport and anti-folate activity in cultured tumor cells.
Topics: Antineoplastic Agents; Biological Transport; Carrier Proteins; Cell Division; Drug Synergism; Folate | 1995 |
[Suramin. A new role for an old drug].
Topics: Antineoplastic Agents; Humans; Neoplasms; Suramin | 1994 |
Postoperative complications in patients receiving suramin therapy.
Topics: Adult; Aged; Aged, 80 and over; Drug Evaluation; Female; Hemorrhage; Humans; Infusions, Intravenous; | 1994 |
Data modifications to phase I study of suramin.
Topics: Antineoplastic Agents; Clinical Trials, Phase I as Topic; Humans; Neoplasms; Suramin | 1996 |
Phase I study of suramin administered by intermittent infusion without adaptive control to cancer patients: update of two expanded dose levels near the maximally tolerated dose.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Clinical Trials, Phase I as Topic; Humans; In | 1996 |
Suramin sodium. CI 1003, Metaret, suramin, suramin hexasodium.
Topics: Animals; Antineoplastic Agents; Drug Interactions; Humans; Male; Mice; Mice, Nude; Neoplasms; Neopla | 1999 |
EGR-1, a UV-inducible gene in p53(-/-) mouse cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Transformed; DNA-Binding Proteins; Early Growt | 2001 |
Demonstration of an activated platelet-derived growth factor autocrine pathway and its role in human tumor cell proliferation in vitro.
Topics: Antibodies; Cell Division; Humans; Neoplasms; Phosphorylation; Platelet-Derived Growth Factor; Recep | 1992 |
Suramin: rapid loading and weekly maintenance regimens for cancer patients.
Topics: Adult; Aged; Ambulatory Care; Bayes Theorem; Drug Administration Schedule; Female; Half-Life; Humans | 1992 |
Antiproliferative effects of suramin on human cancer cells in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Cell Division; Humans; Liver Neoplasms, Experimental; Mice; Mice, Nu | 1992 |
Suramin awakes?
Topics: Humans; Neoplasms; Suramin | 1992 |
The effect of suramin on laboratory tests of coagulation.
Topics: Blood Coagulation; Blood Coagulation Factors; Glycosaminoglycans; Humans; In Vitro Techniques; Infus | 1992 |
Second international symposium on 'Hormonal manipulation of cancer: peptides, growth factors and new (anti)steroidal agents'. Meeting report, April 9-11, 1990, Rotterdam, The Netherlands.
Topics: Growth Inhibitors; Growth Substances; Hormones; Humans; Neoplasms; Peptides; Suramin | 1991 |
Suramin-induced polyneuropathy.
Topics: Adult; Cerebrospinal Fluid Proteins; Female; Humans; Male; Middle Aged; Neoplasms; Neural Conduction | 1990 |
Role of iron in the proliferation of the established human tumor cell lines U-937 and K-562: effects of suramin and a lipophilic iron chelator (PIH).
Topics: Cell Cycle; Cell Division; Cell Line; DNA; Humans; Intracellular Membranes; Iron; Iron Chelating Age | 1986 |